Record Consolidated Revenue and Sales Growth
Reported record Q1 consolidated net sales of $271.0M, up 8.1% year-over-year; ~2% of the sales growth was favorably impacted by foreign currency (stronger euro).
Record Profitability and EPS Expansion
Delivered record GAAP earnings from operations of $56.0M (up 9%), consolidated net income of $40.0M (up 8.7%), GAAP diluted EPS $1.25 (up 10.6%), and adjusted EPS $1.33 (up 9%).
Adjusted EBITDA and Margin Strength
Record adjusted EBITDA of $74.0M, a 12.1% increase year-over-year, with an adjusted EBITDA margin rate of 27.4%.
Gross Margin Expansion
Gross margin dollars of $101.0M, up 14.6%, and gross margin rate expanded to 37.3% of sales (up 210 basis points) driven by sales mix (higher-margin businesses growing faster), manufacturing efficiencies, and price/inflation management.
Segment-Level Growth Across All Businesses
Human Nutrition & Health sales $172M (up 8.3%) with segment OI $40M (up 5.4%); Animal Nutrition & Health sales $62M (up 8.6%) with segment OI $6M (up ~8.7%); Specialty Products sales $35M (up 4.4%) with segment OI $12M (up 24.5%). All three segments delivered year-over-year sales and earnings growth.
Cash Generation and Strong Balance Sheet Metrics
Operating cash flow of $40M, free cash flow of $34M, cash on hand of $73M, net debt $96M and net leverage of 0.3, and net interest expense down $1M to $2M.
Sustainability Milestone
Surpassed 2030 greenhouse gas target early: reduced scope 1 & 2 GHG emissions ~31% vs 2020 baseline (target was 25% by 2030); water withdrawal reduced ~16% vs 2020 baseline.
Continued Momentum in Branded Ingredients and Commercial Expansion
Branded ingredients (e.g., Vidacholine, K2 Vital, Opti MSM) account for ~40-50% of Human Nutrition & Health and are growing faster than other portfolio parts; Vidacholine received new peer-reviewed positive fMRI clinical data supporting cognitive benefits in postmenopausal women, supporting expansion into larger adult cognition markets.
Long Track Record of Margin Growth
Delivered the 27th consecutive quarter of year-over-year growth in adjusted EBITDA, demonstrating consistent operational performance across a volatile multi-year environment.